- CA$24.27m
- CA$28.37m
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units
Brief: Betterlife Receives FDA Response On Its Pre-Ind Application For Major Depressive Disorder (Mdd) Treatment With Betr-001
Brief: Betterlife Obtains Positive In Vivo Oral Bioavailability, Food Effect And Pharmacokinetics Data For Betr-001
Brief: Betterlife Successfully Completes Phase 1 And Initiates Phase 2 Clinical Trials With Interferon Alpha-2B In Covid-19 Patients In Chile
Brief: Early Results Of Betterlife Preclinical Study Show AP-003 (RHIFN⍺2B) Provides Up To 97% Protection In Human Cells Against The Delta Variant Of SARS-COV-2
Brief: Betterlife Pharma Initiates Preclinical Study Of AP-003 (Rhifna2b) Against Delta Variant Of Sars-Cov-2
Brief: Betterlife Secures Mitacs Funding In Collaboration With Carleton University Research Team For Td-0148A Preclinical Depression Studies
Brief: BetterLife Pharma Says Unit Altum Pharmaceuticals Entered Into LOI With Pontificia Universidad Católica de Chile
Brief: Betterlife Pharma - Enters Into Research Agreement With Carleton University For Td-0148A Depression Studies
Brief: BetterLife Pharma Strengthens Board Of Directors
Brief: BetterLife Names CRO For COVID-19 Clinical Trial In Australia
Brief: Betterlife Pharma Says On July 29 91.3% Of Altum Shareholders Voted In Favour Of Merger With Betterlife
Brief: Betterlife Pharma Announces Consolidation Of Its Common Shares
Brief: BetterLife Pharma Says Entered Into Exclusivity Agreement With Altum Pharmaceuticals
Brief: Betterlife Pharma Announces Interferon Alpha-2B Covid-19 News Regarding Its Emergence As Potential Treatment For Covid-19
Brief: Betterlife Pharma Files Site Evidence Package With Health Canada